Head And Neck Squamous Cell Carcinoma
Intervention improves timely postoperative treatment for people with head and neck cancer
A multilevel, navigation-based intervention led to more timely initiation of postoperative radiation therapy vs. usual care-based patient navigation for people with head and neck squamous cell carcinoma.
FDA approves Opdivo as subcutaneous injection
The FDA has approved nivolumab and hyaluronidase-nvhy for subcutaneous injection in adults with solid tumors in which nivolumab is indicated, according to a press release.
Oral bacteria may be biomarker to predict risk for head, neck cancers
Researchers have found evidence that the contents of an individual’s oral microbiome may be associated with their risk for head and neck cancers.
Obesity associated with longer survival in immunotherapy-treated head, neck cancer
An analysis of patients with head and neck squamous cell carcinoma who received immune checkpoint inhibitors showed those with obesity survived longer than those with normal BMI.
‘Sobering’ data show excessive cannabis use increases risk for head and neck cancer
Individuals with cannabis-related disorder exhibited increased risk for head and neck cancer, results of a retrospective cohort study showed.
Trial of vaccine plus pembrolizumab for head/neck cancer misses endpoint
The addition of an investigational cancer vaccine to pembrolizumab failed to improve outcomes for patients with metastatic or recurrent head and neck squamous cell carcinoma, according to the agent’s manufacturer.
‘Best expectation’: Vaccine responses may prevent, delay cancer relapse
A personalized cancer vaccine produced T-cell responses in certain patients with head and neck squamous cell carcinoma, according to results from a randomized study presented at American Association for Cancer Research Annual Meeting.
FDA grants breakthrough designation to colorectal cancer agent, fast tracks HNSCC therapy
The FDA announced several regulatory actions the past few weeks.
Combination exhibits ‘impressive’ activity in HPV-negative head and neck cancer
The combination of ficlatuzumab and cetuximab extended PFS for patients with pan-refractory recurrent or metastatic head and neck squamous cell carcinoma, according to randomized phase 2 study results.
ESMO presentations highlight advances in kidney cancer, melanoma, lung cancer
This year’s European Society for Medical Oncology Congress featured potentially practice-changing research in kidney cancer, cutaneous squamous cell carcinoma, lung cancer and melanoma.